Integrated Chinese and western medicine for acute guillain-barré syndrome treatment

Abstract

<jats:title>Abstract</jats:title><jats:sec id="j_tnsci-2020-0007_s_006_w2aab3b7c24b1b6b1aab1c16b1Aa"><jats:title>Introduction</jats:title><jats:p>Guillain-Barré syndrome (GBS) is a worldwide demyelinating polyradiculopathy and polyneuropathy. Currently, there is no specific drug for GBS, and established treatment is generally based on immune-modulating treatment with plasma exchange or intravenous immunoglobulin in combination with supportive care. This study aimed to investigate the efficiency of integrated Chinese and Western medicine for acute GBS treatment.</jats:p></jats:sec><jats:sec id="j_tnsci-2020-0007_s_007_w2aab3b7c24b1b6b1aab1c16b2Aa"><jats:title>Methods</jats:title><jats:p>We enrolled 73 subjects, and randomly divided them into two groups: 35 cases in the traditional Chinese medicine (TCM) group, and 28 in the Control group. The Control group was treated with the common Western medicine for one month; and the TCM group was administrated with one month of common treatment combined with TCM medication.</jats:p></jats:sec><jats:sec id="j_tnsci-2020-0007_s_008_w2aab3b7c24b1b6b1aab1c16b3Aa"><jats:title>Results</jats:title><jats:p>Compared to the controls, TCM significantly enhanced the treatment efficiency in symptom expression, including the TCM syndrome score, the activity of daily living score, Hughes functional score and sensory dysfunction assessment. The total effective rate of the TCM group was 94.29%, significantly better than controls (78.59%). Moreover, TCM provide better improvement in motor nerve conduction functions (distal motor latency and motor conduction velocity) and sensory nerve conduction functions (sensory conduction velocity and sensory nerve action potential) in median nerve, ulnar nerve, and common fibular nerve.</jats:p></jats:sec><jats:sec id="j_tnsci-2020-0007_s_009_w2aab3b7c24b1b6b1aab1c16b4Aa"><jats:title>Conclusion</jats:title><jats:p>When combined with TCM administration, the GBS treatment could acquire better outcomes.</jats:p></jats:sec>

Network pharmacology analysis of the mechanism of our hospital’s experiential prescription in the treatment of Guillain Barré syndrome

“…At present, there is no specific drug for GBS, and established treatment is generally based on immunemodulating treatment with plasma exchange or intravenous immunoglobulin in combination with supportive care (11)(12)(13). Recently, some novel drugs have been reported to be potentially effective, such as memantine, bifidobacterium, gabapentin, etc.…”

Celastrol attenuates Guillain-Barré syndrome by inhibiting TLR4/NF-κB/STAT3 pathway-mediated Th1/Th17 cell differentiation

“…However, effective supporting therapeutic strategies for GBS, such as traditional Chinese medicine (TCM) approaches, are still urgently required. Previous research has suggested that the integration of an empirical TCM strategy and the current treatment could have a better effect on GBS (Yang and Zhao 2020).…”